Novel approach in radionuclide tumor therapy: Dose enhancement by high Z-element contrast agents

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 3, 2006, Pages 181-193

  Aziz, Emad F ^a   Bugaj, Joseph E ^b,c   Caglar, Gül ^b   Dinkelborg, Ludger M ^b   Lawaczeck, Rüdiger ^b  

^a HAHN MEITNER INSTITUT   (Germany)

^b BAYER PHARMA AG   (Germany)

^c BAYER AG   (Germany)

Author keywords

Contrast media; Dose enhancement; Monte carlo simulation; Peptides; Radiation therapy; Radionuclides

Indexed keywords

BOMBESIN DERIVATIVE; CONTRAST MEDIUM; GADOBUTROL; GADOLINIUM; IODINE; IOPROMIDE; LUTETIUM 177; P 2045; P 2349; RADIOACTIVE IODINE; RADIOISOTOPE; RADIOSENSITIZING AGENT; RHENIUM 188; UNCLASSIFIED DRUG;

ARTICLE; BEAM THERAPY; CANCER RADIOTHERAPY; CELL STRAIN; CELL SURVIVAL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; ELECTRON; ELECTRON GAMMA SHOWER; HUMAN; HUMAN CELL; IONIZING RADIATION; MONTE CARLO METHOD; PARTICLE RADIATION; PRIORITY JOURNAL; QUALITY CONTROL; RADIATION DOSE; SOLID TUMOR; TUMOR LOCALIZATION;

CELL LINE, TUMOR; CELL SURVIVAL; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MODELS, CHEMICAL; MODELS, THEORETICAL; MONTE CARLO METHOD; NEOPLASMS; PEPTIDES; PHOTONS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; SOFTWARE;

EID: 33746369796     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.181     Document Type: Article

References (56)

1. Webb S. Conformal intensity-modulated radiotherapy (IMRT) delivered by robotic linac-testing IMRT to the limit? Phys Med Biol 1999;44:1639.
2. Webb S. Conformal intensity-modulated radiotherapy (IMRT) delivered by robotic linac-conformality versus efficiency of dose delivery. Phys Med Biol 2000;45:1715.
3. Didinger BH, Schlegel W, Debus J. Intensity-modulated radiotherapy-technology and clinical applications. Onkologie 2002;25:233.
4. Wheldon TE, Odonoghue JA. The radiobiology of targeted radiotherapy. Int J Rad Biol. 1990;58:1.
5. 0] octreotide: The Rotterdam Experience. Semin Nucl Med 2002;32:110.
6. Anthony LB, Woltering EA, Espanan GD, et al. Indium-111-pentreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002;32:123.
7. Bugaj JE, Friebe M, Cyr JE, et al. Radiotherapeutic efficacy of Re-P2045 in small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) mouse models by specific SSTR-targeting. In: Nicolini M, Mazzi U, (eds.). Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine. 6th ed. Padova, Italy: SGEditorali, 2002;357.
8. Hoefnagel C. Radionuclide cancer therapy. Ann Nucl Med 1998;12:61.
9. 90Y-DOTATOC) in the treatment of neuroendocrine tumors: A clinical phase II study. Ann Oncol 2001;12:941.
10. Chen FD, Hsieh BT, Wang HE, et al. Efficacy of Re-188-labelled sulphur colloid on prolongation of survival time in melanoma-bearing mice. Nucl Med Biol 2001;28:835.
11. Li S, Liu J, Zhang H, et al. Rhenium-188 HEDP to treat painful bone mestases. Clin Nucl Med 2001;26:919.
12. 0]octreotide in patients. EJ Nucl Med 2001;28: 1319.
13. 3]octreotate in patients with endocrine gasteoenteropancreatic tumors. J Clin Oncol 2005;23:2754.
14. Volkert W, Goeckeler WF, Ehrhardt GJ, et al. Therapeutic radionuclides: Production and decay property considerations. J Nucl Med 1991;32:174.
15. Zweit J. Radionuclides and carrier molecules for therapy. Phys Med Biol 1996;41:1905.
16. McDevitt M, Sgouros G, Finn R, et al. Radioimmunotherapy with alpha-emitting nuclides. EJ Nucl Med 1998;25:1342.
17. Allen BJ, Blagojevic N. Alpha and beta-emitting radiolanthamides in targeted cancer therapy: The potential role of terbium-149. Nucl Med Commun 1996;17:40.
18. Zackrisson B, Kjellen E, Glimelius B, et al. Sensitizing and protective substances in radiation therapy and predictive assays. Acta Oncol 2002;41:615.
19. Fairchild RG, Bond VP. New compounds for neutron-capture therapy (Net) and their significance. Strahlentherapie 1984;160:764.
20. Fairchild RG, Laster BH, Popenoe EA, et al. Photon-activation therapy (PAT). Med Phys 1985;12:536.
21. Barth RF, Soloway AH, Fairchild RG, et al. Boron neutron-capture therapy for cancer-realities and prospects. Cancer 1992;70:2995.
22. Mesa AV, Norman A, Solberg TD, et al. Dose distributions using kilovoltage x-rays and dose enhancement from iodine contrast agents. Phys Med Biol 1999;44: 1955.
23. Laster BH, Thomlinson WC, Fairchild RG. Photon-activation of Iododeoxyuridine-biological efficacy of Auger electrons. Radiat Res 1993;133:219.
24. Solberg TD, Iwamoto KS, Norman A. Calculation of radiation-dose enhancement factors for dose enhancement therapy of brain tumors. Phys Med Biol 1992;37:439.
25. Lawaczeck R, Diekmann C, Hofmann B, et al. Tumor therapy with radiation-absorbing substances: Activation by X-photons and use of Gd complexes. Am Assoc Cancer Res 2000;41:371.
26. Krenning EP, Kwekkeboom DJ, Valkema R, et al. Peptide receptor radionuclide radiotherapy. Ann NY Acad Sci 2004;1014:234.
27. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of peptide receptor radionuclide radiotherapy with three radiolabeled somatostatin analogs. J Nucl Med 2005;46:62S.
28. Lau SK, Johnson DS, Coel MN. Imaging of non-small-cell lung cancer with indium-111 pentetreotide. Clin Nucl Med 2000;25:24.
29. 3-Octreotide-the Rotterdam Experience with more than 1000 patients. EJ Nucl Med 1993;20:716.
30. Forssell-Aronsson E, Bernhardt P, Nilsson O, et al. Biodistribution data from 100 patients i.v. injected with In-111-DTPA-D-Phe(1)-octreotide. Acta Oncol 2004; 43:436.
31. Bugaj JE, Erion JL, Johnson MA, et al. Radiotherapeutic efficacy of Sm-153-CMDTPA-Tyr(3)-octreotate in tumor-bearing rats. Nucl Med Biol 2001;28:327.
32. 3-octreotate: Tumor response and kidney function after radionuclide therapy in different rat tumor models. J Nucl Med 2001;42:314.
33. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: First clinical results. E J Nucl Med 1999;26:1439.
34. Waldherr C, Pless M, Mäcke H, et al. The clinical value of [Y-90-DOTA]-D-Phe(1)-Tyr(3)-octreotide (Y-90-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study. Ann Oncol 2001;12:941.
35. Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [Lu-177-DOTA(0),Tyr(3)]octreotate. E J Nucl Med Mol Imaging 2003;30:417.
36. Kawrakow I, Rogers D. The EGSnrc Code System: Monte Carlo Simulation of Electron and Photon Transport. NRCC Report, Ionizing Radiation Standards, National Research Council of Canada, 2003.
37. Walters B, Kawrakow I, Rogers D. DOSXYZnrc User's Manual Ionizing Radiation Standards, National Research Council of Canada, Ottawa, Canada, 2005.
38. Williamson J. Recent developments in basic brachytherapy physics. In: Smith AR, ed. Radiation Therapy Physics. New York. Springer-Verlag, 1995;247.
39. Bielajew AF. On the technique of extrapolation to obtain wall correction factors for ion chambers by photon beams. Med Phys 1990;17:583.
40. Kawrakow I. Accurate condensed history Monte Carlo simulation of electron transport. I. EGSnrc, the new EGS4 version. Med Phys 2000;27:485.
41. Janicki C, Seuntjens J. Reevaluation of the dose to the cyst wall in P-32 radiocolloid treatments of cystic brain tumors using the Dose-Point-Kernel and Monte Carlo methods. Med Phys 2003;30:2475.
42. Rogers D, Bielajew A. The Use of EGS for Monte-Carlo Calculations in medical physics. Med Phys 1984;11:417.
43. Kiefer J. Biological Radiation Effects. Berlin/Heidelberg. Springer-Verlag, 1990.
44. Johns HE, Cunningham JR. The Physics of Radiology (4th ed.). Chicago, IL: Charles C. Thomas, 1983.
45. Nelson WR, Hirayama H, Rogers DWO. The EGS4 code system. Report SLAC-265, Stanford Linear Accelerator Center, 1985.
46. Walters BRB, Treurniet J, Rogers DWO, et al. QA tests and comparisons of the EGSnrc system with EGS4. Technical Report PIRS-703, National Research Council of Canada, 2000.
47. Ford RL, Nelson WR. The EGS code system-version 3. Stanford Linear Accelerator Center Report SLAC-210, 1978.
48. Berger MJ. Monte Carlo calculation of the penetration and diffusion of fast charged particles. In: Alder B, Fernbach S, Rotenberg M, (eds.). Methods in Comput. Phys., Vol. 1. 1963, New York: Academic Press, 1963:135.
49. Orion I, Wielopolski L. Limitations in the PHOTON Monte Carlo gamma transport code. Nuclear Instruments & Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment. 2002;480:729.
50. Rogers DWO. Low-energy electron transport with EGS. Nuclear Instruments & Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment 1984;227:535.
51. 111In-DTPA-octreotide. J Nucl Med 2003;44:98.
52. 90Y: Peptide receptor radionuclide therapy results in vitro. Cancer Biother Radiopharm 2003;18(5):761.
53. Capello A, Krenning E, Bernard B, et al. Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog. J Nucl Med 2004;45(10):1716.
54. Verwijnen S, Capello A, Bernard B, et al. Low-dose-rate irradiation by I-131 versus high-dose-rate external-beam irradiation in the rat pancreatic tumor cell line CA20948. Cancer Biother Radiopharm 2004;19:285.
55. 90Y-biotin radioimmunotherapy and temozolomide. QJ Nucl Med 2004; 48:220.
56. Boiardi A, Bartolomei M, Silvani A, et al. Intratumoral delivery in association with 90-Y radioimmunotherapy (RIT) in recurrent glioma. J Neuro-Oncol 2005;72:125.